TRK inhibitors: managing on-target toxicities
- PMID: 32574723
- DOI: 10.1016/j.annonc.2020.06.010
TRK inhibitors: managing on-target toxicities
Conflict of interest statement
Disclosures JSJL received consultancy fees and honoraria from Pfizer, AstraZeneca and Novartis and received government funding from National Medical Research Council (NMRC) Transition award (MOH-TA19may-0004). DSPT received consultancy fees and honoraria from AstraZeneca, Roche, Bayer, MSD, Merck Serono, Tessa Therapeutics and Genmab; research funding from AstraZeneca, Bayer and Karyopharm (no grant numbers) and received government fundings from NMRC Clinician Scientist Award (NMRC/CSA-INV/0016/2017).
Comment on
-
Characterization of on-target adverse events caused by TRK inhibitor therapy.Ann Oncol. 2020 Sep;31(9):1207-1215. doi: 10.1016/j.annonc.2020.05.006. Epub 2020 May 15. Ann Oncol. 2020. PMID: 32422171 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
